A Phase 2/3 interventional study of Pharmacokinetic based dosage change and Pharmacokinetic dosing in Sickle Cell Disease (SCD), sponsored by Yves Pastore. Recruiting at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Yves Pastore · Phase 2/3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Anemia, Sickle Cell with a site in Canada — 15 open to participants now, 22 under way, 7 of them phase 3. Anemia, Sickle Cell · Canada.
Among the 55 studies in Anemia, Sickle Cell with a site in Canada, this one is the 44th largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 14 of the 21 other live ones, and was the 52nd registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 55 studies in Anemia, Sickle Cell with a site in Canada are open now. Recruiting first, the newest first:
Biossil Inc. · Sites in Canada
Ages 16–50
Novo Nordisk A/S · Sites in Canada, United States, Australia and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in Canada, United States, Egypt and 14 more countries
Ages 2+
Bristol-Myers Squibb · Sites in Canada, United States, France and 2 more countries
Ages 18+ · Healthy volunteers
University of Rochester · Sites in Canada, United States
Ages 3–20
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 6 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 27 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 29 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 81 across the 49 interventional studies, 300 across the 5 observational. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 55 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yves Pastore as lead sponsor.
Yves Pastore has 1 study filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia, Sickle Cell with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06481306Bristol-Myers SquibbA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | 2027-01-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Anemia, Sickle Cell with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate if patients with sickle cell disease can achieve a maximum tolerate dose of hydroxuyrea (HU) over a period of 12 months faster with pharmacokinetic testing than the standard of care bloodwork follow-up. Pharmacokinetic test is used to evaluate the process by which drugs are absorbed, distributed in the body, localized in the tissues, and is excreted.
Patient will be a randomized (coin toss method) into 2 groups. Group A will have an increase of their HU dosage with pharmacokinetic results and Group B will have an increase of their HU dosage following the standard of care bloodwork follow-up.
Group C will include patient with sickle cell disease that has been taking HU for at least 12 months and will undergo a pharmacokinetic dosage to check the level of HU only one time.
Inclusion Criteria (Group A and B) :
Inclusion Criteria (Group C) :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient starting hydroxyurea that will have PK sample procurements at different timpoints over a period of 12 months until HU-AUC shows MTD
Diagnostic Test: Pharmacokinetic based dosage change
Patient starting hydroxuyrea that will be followed as per standard of care over a period of 12 months until MTD has been reached
Patient will undergo one PK sample procurement to evaluate level of HU-AUC after 12 months of taking hydroxyurea.
Diagnostic Test: Pharmacokinetic dosing
This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B
Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint
Evaluation of HU-PK at 6 months between group A and group B
Pharmakocinetic dosage of hydroxyurea will be determined at 6 months in group A and group B. The investigator hypothesize that HU-PK in group B may be lower (suboptimal) compared to group A.
Time frame: At 6 months
Time to reach maximal tolerated dose (MTD)
Time (weeks) to achieve MTD in groups A and B will be determined by evaluating the % of patients reaching MTD (at 3 , 6, 9 and 12 months) in each group. MTD is defined by hematological parameters: Absolute neutrophile count 0.8-1.5x10\*9/L or platelet 80-120x10\*9/L or absolute reticulocyte count 50-80x10\*9/L)
Time frame: 3, 6, 9 and 12 months
Fetal hemoglobin
Comparing fetal hemoglobin between group A and B
Time frame: at 3, 6 and 12 months
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in group A and B
Evaluation of the incidence adverse events (AE) and serious adverse events (SAE) in both groups
Time frame: From enrollment to 12 months
Evaluation of % of patients reaching AUC of 115 +/- 15mg*h/L at 12 months compared to the percentage of patients in group C reaching the same AUC
Percentage of patients in the HU-AUC (group A) with an AUC of 115 mg\*h/L at 12 months will be compared to the percentage of patients in group C with an AUC of 115 +/-15 mg\*h/L.
Time frame: At 12 months
Plan to share: No — This is a pilot study with a small group of participant.
Started Feb 2026 (actual). Primary completion is estimated for Nov 2028, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.